Recent developments highlight INVO Fertility's expansion of fertility services, strategic acquisitions, financial reporting, and corporate actions including reverse stock splits and patent issuances.

• INVO Fertility enhanced fertility services with expanded training and improved pricing for the INVOcell device [N5].
• The company expanded fertility services by introducing platelet-rich plasma therapy at the Wisconsin Fertility Institute [N6].
• INVO Fertility expanded telehealth services to improve access to expert fertility care in multiple states [N7].
• INVO Fertility reported Q1 2025 financial results focusing on core fertility operations [N8].
• The company reported record revenue growth in Q4 2024 and full year 2024 financial results [N8].
• INVO Fertility announced and implemented a 1-for-3 reverse stock split effective July 21, 2025, with plans for additional reverse stock splits in 2025 [N3][N4].
• INVO Fertility shares surged following patent issuance for a modified INVOcell device [N1].
• The company’s shares soared over 300% in early 2026 [N2].

INVO Fertility has demonstrated growth through service expansion, including new therapies and telehealth access, and has secured intellectual property protections for its fertility devices. The company’s strategic acquisitions and management agreements may strengthen its operational footprint. Recent financial results indicate revenue growth and positive net income, suggesting operational progress. The company’s leadership team has relevant industry and financial expertise, supporting execution capabilities.

The company’s liquidity ratios as of December 31, 2025, indicate current liabilities significantly exceed current assets, which may pose short-term financial challenges. The reported negative earnings per share despite net income suggests complexities in share count or accounting treatments. The fertility services market is subject to regulatory, reimbursement, and competitive risks. The company has engaged in multiple reverse stock splits, which may reflect challenges in maintaining share price levels. Financial statement restatements and accounting errors noted in prior periods may indicate operational or reporting risks.

INVO Fertility's moat is supported by its proprietary INVOcell device, for which it holds patents including recent modifications, providing intellectual property protection. The company's expansion into novel fertility therapies and telehealth services enhances its service offering and geographic reach. Long-term management agreements and acquisitions of clinical assets contribute to operational integration and potential competitive advantages in fertility services. However, the fertility services market is competitive and subject to regulatory and reimbursement challenges.

• Liquidity Risk: As of December 31, 2025, the company’s current ratio was 0.27 and cash ratio was 0.19, indicating current liabilities substantially exceed current assets, which may impact short-term financial flexibility.
• Regulatory and Market Risks: The fertility services industry is subject to regulatory changes, reimbursement policies, and competitive pressures that could affect operations and financial results.
• Accounting and Reporting Risks: The company identified and is restating prior financial statement errors related to derivative accounting, equity classification, and debt extinguishment, which may affect investor confidence and financial clarity.
• Stock Structure and Market Perception: Multiple reverse stock splits have been implemented, which may affect shareholder perception and reflect challenges in maintaining share price and market capitalization.

• INVO Fertility, Inc. is a publicly traded company on Nasdaq under the ticker IVF [S1].
• The company operates in the fertility services sector, providing fertility-related medical services and products [N5][N6][N7].
• INVO Fertility has expanded its fertility services by introducing platelet-rich plasma therapy at the Wisconsin Fertility Institute [N6].
• The company has enhanced fertility services with expanded training and improved pricing for its INVOcell device [N5].
• INVO Fertility has expanded telehealth services to improve access to expert fertility care across multiple states [N7].
• The company completed the acquisition of Family Beginnings P.C. and related clinical assets in early 2026, including entering into a Management Services Agreement for operation of medical practices [S1].
• INVO Fertility announced and implemented a 1-for-3 reverse stock split effective July 21, 2025, and planned further reverse stock splits in 2025 [N3][N4].
• The company reported record revenue growth in Q4 2024 and full year 2024 financial results [N8].
• INVO Fertility reported Q1 2025 financial results with a strategic focus on core fertility operations [N8].
• The company’s financial snapshot as of December 31, 2025, includes revenue of approximately $6.84 million USD and net income of approximately $23.32 million USD, with a basic and diluted EPS of -214.64 USD per share [S1].
• As of December 31, 2025, INVO Fertility had cash and equivalents of approximately $1.96 million USD, current assets of about $2.76 million USD, and current liabilities of about $10.33 million USD, resulting in a current ratio of 0.27 and a cash ratio of 0.19 [S1].
• The company’s board includes CEO Steven Shum and other executives with diverse backgrounds in finance, business, and life sciences [S1].
• INVO Fertility holds patents related to its INVOcell device, with recent patent issuance for a modified version of the device [N1].
• The company’s shares experienced significant price appreciation, soaring over 300% in early 2026 [N2].
• INVO Fertility has a Code of Business Conduct and Ethics applicable to all employees and directors, available on its website [S1].